⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AKTX News
Akari Therapeutics plc ADR (0.01 USD)
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026
globenewswire.com
AKTX
Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance
globenewswire.com
AKTX
Form 8-K
sec.gov
AKTX
This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners
globenewswire.com
AKTX
NTHI
MTVA
HCWB
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
globenewswire.com
AKTX
Akari Therapeutics Announces $5.5 Million Private Placement Offering
globenewswire.com
AKTX
Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase
globenewswire.com
AKTX
HEALIOS K.K. to Present at Jefferies Global Healthcare Conference
globenewswire.com
AKTX
Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets
globenewswire.com
AKTX
Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload
globenewswire.com
AKTX